UK Embraces, Germany Cuts: Europe Splits on Drug Prices
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- U.K. government adopted more industry-friendly drug pricing policies after a pressure campaign from both pharma companies and the Trump administration, and has also promised to spend more on medicines.
- Germany is heading in the opposite direction, with the government proposing moves that would cut health spending and increase the fees the pharma industry must pay.
- Germany's proposed spending cuts are driven by growing deficits in its health budget, a fiscal squeeze not cited as a factor in the U.K.'s shift.
- The diverging approaches in the U.K. and Germany — two of Europe's biggest drug markets — are testing the influence of the U.S. on pharmaceutical pricing policy across the continent.
- The policy split affects pharma companies and patients continent-wide, with London's two biggest European markets now moving in opposite directions on drug costs.
Why it matters: Pharma companies gain a friendlier pricing partner in London but face steeper fees and tighter budgets in Berlin, reshaping revenue calculus across Europe's two biggest drug markets. Germany's health budget deficits are forcing concrete cuts and higher industry fees, while the U.K. is loosening policy under Trump administration pressure — meaning patients, payers, and pharma face materially different outcomes depending on which side of the channel they're on.
Ask SkimNews
